Steven J. Isakoff

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Biomarker-driven prescribing patterns in <i>ESR1</i> <i> ^mut </i> ER+/HER2- metastatic breast cancer (mBC).

  Journal of Clinical Oncology · 2026-05-28

• A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.

  Journal of Clinical Oncology · 2026-05-27

• Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.

  Journal of Clinical Oncology · 2026-05-27

• Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

  The Lancet Oncology · 2026-04-27

• Abstract CT045: Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer

  Cancer Research · 2026-04-17

• TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer

  Journal for ImmunoTherapy of Cancer · 2026-04-01 · 2 citations

• PS5-09-16: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+/HER2- MBC (START-002 trial)

  Clinical Cancer Research · 2026-02-17

• 665 TROP2 remodeling of the immune microenvironment in triple negative breast cancer

  Regular and Young Investigator Award Abstracts · 2025-11-01

• A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer 2059

  The Journal of Immunology · 2025-11-01

• Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer

  JNCI Cancer Spectrum · 2025-09-01

• Selection biases in the systematic collection of breast biobank specimens

  npj Breast Cancer · 2025-08-01 · 1 citations

• Abstract PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial

  Clinical Cancer Research · 2025-06-13 · 2 citations

• Abstract P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy &amp; a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial

  Clinical Cancer Research · 2025-06-13

• Abstract P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis

  Clinical Cancer Research · 2025-06-13

• Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+/HER2- Cohort

  Clinical Cancer Research · 2025-06-13 · 4 citations

• A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy.

  Journal of Clinical Oncology · 2025-05-28

• A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

  Journal of Clinical Oncology · 2025-05-28 · 11 citations

• Supplemental Table S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Data from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15